Ex vivo gene therapy and vision

Current Gene Therapy

Volumn 12, Issue 2, 2012, Pages 103-115

  Gregory Evans, Kevin ^a   Bashar, A M A Emran ^a   Tan, Malcolm ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Brain; Ex vivo gene therapy; Eye

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOSTATIN; ERYTHROPOIETIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 10; INTERLEUKIN 4; KRINGLE 5; LENTIVIRUS VECTOR; NEUROGENIC DIFFERENTIATION FACTOR; NEUROGENIN 1; NEUROGENIN 3; PIGMENT EPITHELIUM DERIVED FACTOR; PLASMA PROTEIN; PROTEIN BCL XL; PROTEIN CRX; PROTEIN MOG; PROTEIN NRL; PROTEIN P35; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS VECTOR;

BLINDNESS; CELL TYPE; CORNEA DISEASE; EX VIVO STUDY; GENE DOSAGE; GENE THERAPY; GLAUCOMA; HUMAN; MULTIPLE SCLEROSIS; QUALITY OF LIFE; RETINA DEGENERATION; REVIEW; STROKE; VISION;

ANIMALS; EYE DISEASES; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; STEM CELL TRANSPLANTATION; STEM CELLS; VISION, OCULAR;

EID: 84860309588     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312800099607     Document Type: Review

References (205)

1. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28: 92-5.
2. Smith AJ, Schlichtenbrede FC, Tschernutter M, Bainbridge JW, Thrasher AJ, Ali RR. AAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. Mol Ther 2003; 8: 188-95.
3. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358: 2231-9.
4. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-8.
5. Ashtari M, Cyckowski LL, Monroe JF, et al. The human visual cortex responds to gene therapy-mediated recovery of retinal function. J Clin Invest 2011; 121: 2160-8.
6. McCormack MP, Rabbitts TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004; 350: 913-922.
7. Kaiser J. Clinical trials. Gene transfer an unlikely contributor to patient's death. Science 2007; 318: 1535.
8. Smith RH. Adeno-associated virus integration: virus versus vector. Gene Ther 2008; 15: 817-822.
9. Bushman FD. Retroviral integration and human gene therapy. J Clin Invest 2007; 117: 2083-2086.
10. Gerrard AJ, Hudson DL, Brownlee GG, Watt FM. Towards gene therapy for haemophilia B using primary human keratinocytes. Nat Genet 1993; 3: 180-183.
11. Fenjves ES, Yao SN, Kurachi K, Taichman LB. Loss of expression of a retrovirus-transduced gene in human keratinocytes. J Invest Dermatol 1996; 106: 576-578.
12. Sorrentino BP. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nature Rev Cancer 2002; 2: 431-41.
13. De Palma M, Mazzieri R, Politi LS, et al. Tumor-targeted interferon-α delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008; 14: 299-311.
14. Biffi, A, Capotondo A, Fasano S, et al. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest 2006; 116: 3070-82.
15. Visigalli I, Delai S, Politi LS, et al. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 2010; 116: 5130-9.
16. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489-500.
17. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
18. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-33.
19. Qu D, Li J, Li Y, et al. Angiogenesis and osteogenesis enhanced by bFGF ex vivo gene therapy for bone tissue engineering in reconstruction of calvarial defects. J Biomed Mater Res A 2011; 96: 543-51.
20. Kerns HM, Ryu BY, Stirling BV, et al. B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia. Blood 2010; 115: 2146-55.
21. Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010; 363: 1918-27.
22. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 2011; 12: 301-15.
23. Geller SF, Ge PS, Visel M, Flannery JG. In vitro analysis of promoter activity in Muller cells. Mol Vis 2008; 14: 691-705.
24. Atkinson H, Chalmers R. Delivering the goods: viral and non-viral gene therapy systems and the inherent limits on cargo DNA and internal sequences. Genetica 2010; 138: 485-98.
25. Rolling F. Recombinant AAV-mediated gene transfer to the retina: gene therapy perspectives. Gene Ther 2004;11 Suppl 1:S26-32.
26. Martin KR, Klein RL, Quigley HA. Gene delivery to the eye using adeno-associated viral vectors. Methods 2002; 28:267-75.
27. Mejía-Toiber J, Castillo CG, Giordano M. Strategies for the development of cell lines for ex vivo gene therapy in the central nervous system. Cell Transplant. 2010; 20: 983-1001.
28. Onifer SM, White LA, Whittemore SR, Holets VR. In vitro labeling strategies for identifying primary neural tissue and a neuronal cell line after transplantation in the CNS. Cell Transplant 1993; 2: 131-49.
29. Cashman SM, McCullough L, Kumar-Singh R. Improved retinal transduction in vivo and photoreceptor-specific transgene expression using adenovirus vectors with modified penton base. Mol Ther 2007; 15: 1640-46.
30. Beltran WA, Boye SL, Boye SE, et al. rAAV2/5 gene-targeting to rods:dose-dependent efficiency and complications associated with different promoters. Gene Ther 2010; 17: 1162-74.
31. Li M, Husic N, Lin Y, et al. Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells. J Neurosci Methods 2010; 189: 56-64.
32. Urtti A, Polansky J, Lui GM, Szoka FC. Gene delivery and expression in human retinal pigment epithelial cells: effects of synthetic carriers, serum, extracellular matrix and viral promoters. J Drug Target 2000; 7: 413-21.
33. Harvey BK, Chen GJ, Schoen CJ, et al. An immortalized rat ventral mesencephalic cell line, RTC4, is protective in a rodent model of stroke. Cell Transplant 2007; 16: 483-91.
34. Johansen J, Rosenblad C, Andsberg K, et al. Evaluation of Tet-on system to avoid transgene down-regulation in ex vivo gene transfer to the CNS. Gene Ther 2002; 9: 1291-301.
35. Boulos S, Meloni BP, Arthur PG, Bojarski C, Knuckey NW. Assessment of CMV, RSV and SYN1 promoters and the woodchuck post-transcriptional regulatory element in adenovirus vectors for transgene expression in cortical neuronal cultures. Brain Res 2006; 1102: 27-38.
36. Liu BH, Wang X, Ma YX. Wang, S. CMV enhancer/human PDGFbeta promoter for neuron-specific transgene expression. Gene Ther 2004; 11: 52-60.
37. Mao H, James T Jr, Schwein A, et al. AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa. Hum Gene Ther 2011; 22: 567-75.
38. Hong S, Hwang DY, Yoon S, et al. Functional analysis of various promoters in lentiviral vectors at different stages of in vitro differentiation of mouse embryonic stem cells. Mol. Ther 2007; 15:1630-9.
39. McGee Sanftner LH, Rendahl KG, Quiroz D, et al. Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina. Molecular Ther 2001; 3: 688-96.
40. Williams KA, Coster DJ. Gene therapy for diseases of the cornea-a review. Clin Exp Ophth 2010; 38: 93-103.
41. Chung DC, Lee V, Maguire AM. Recent advances in ocular gene therapy. Curr Opin Ophth 2009; 20:377-81.
42. Buch PK, Bainbridge JW, Ali RR. AAV-mediated gene therapy for retinal disorders: from mouse to man. Gene Ther 2008; 15:849-57.
43. Stieger K, Chauveau C and Rolling F. Preclinical Studies on Specific Gene Therapy for Recessive Retinal Degenerative Diseases. Curr Gene Ther 2010; 10: 389-403.
44. Schambach A and Baum C. Clinical Application of Lentiviral Vectors-Concepts and Practice. Curr Gene Ther 2008; 8: 474-82.
45. Allocca M, Doria M, Petrillo M, et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest 2008; 118: 1955-64.
46. Merten OW, Charrier S, Laroudie N, et al. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 2001; 22: 343-56.
47. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in Xlinked adrenoleukodystrophy. Science 2009; 326: 818-23.
48. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010; 467: 318-22.
49. Parker DG, Coster DJ, Brereton HM, et al. Lentivirus-mediated gene transfer of interleukin 10 to the ovine and human cornea. Clin Exp Ophth 2010; 38: 405-13.
50. Konig Merediz SA, Zhang EP, Wittig B, Hoffmann F. Ballistic transfer of minimalistic immunologically defined expression constructs for IL-4 and CTLA4 into the corneal epithelium in mice after orthotopic corneal allograft transplantation. Graefe's Arch Clin Exp Ophthalmol 2000; 238: 701-707
51. Gregory-Evans K, Chang F, Hodges MD, Gregory-Evans CY. Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration. Mol Vis 2009; 15:962-73.
52. Qin L, Pahud DR, Ding Y, et al. Efficient transfer of genes into murine cardiac grafts by Starburst polyamidoamine dendrimers. Hum Gene Ther 1998; 9: 553-60.
53. Dannowski H, Bednarz J, Reszka R, Engelmann K, Pleyer U. Lipid-mediated gene transfer of acidic fibroblast growth factor into human corneal endothelial cells. Exp Eye Res 2005; 80: 93-101.
54. Lee CY, Li JF, Liou JS, Charng YC, Huang YW, Lee HJ. A gene delivery system for human cells mediated by both a cellpenetrating peptide and a piggyback transposase. Biomaterials 2011; 32: 6264-76.
55. Ye L, Haider HK, Tan R, et al. Transplantation of nanoparticle transfected skeletal myoblasts overexpressing vascular endothelial growth factor-165 for cardiac repair. Circulation 2007; 116: I113-20.
56. Thumann G, Stocker M, Maltusch C, et al. High efficiency nonviral transfection of retinal and iris pigment epithelial cells with pigment epithelium-derived factor. Gene Ther 2010; 17: 181-9.
57. Andre FM and Mir LM. Nucleic Acids Electrotransfer In Vivo: Mechanisms and Practical Aspects. Curr Gene Ther 2010; 10: 267-80.
58. Chalberg TW, Vankov A, Molnar FE, et al. Gene transfer to rabbit retina with electron avalanche transfection. Invest Ophth Vis Sci 2006; 47: 4083-90.
59. Seternes T, Sorensen K, Smedsrod B. Scavenger endothelial cells of vertebrates: a nonperipheral leukocyte system for high-capacity elimination of waste macromolecules. Proc Natl Acad Sci USA 2002; 99: 7594-7.
60. Schafer J, Hobel S, Bakowsky U, Aigner A. Liposomepolyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials 2010; 31: 6892-900.
61. Goomer RS, Deftos LJ, Terkeltaub R, et al. High-efficiency nonviral transfection of primary chondrocytes and perichondrial cells for ex-vivo gene therapy to repair articular cartilage defects. Osteoarthr Cartilage 2001; 9: 248-56.
62. Pleyer U, Dannowski H. Delivery of genes via liposomes to corneal endothelial cells. Drug News Perspec 2002; 15: 283-9.
63. Ziello JE, Huang Y, Jovin IS. Cellular endocytosis and gene delivery. Mol Med 2010; 16: 222-9.
64. Fu C, Sun X, Liu D, Chen Z, Lu Z, Zhang N. Biodegradable Tri-Block Copolymer Poly(lactic acid)-poly(ethylene glycol)-poly(llysine)(PLA-PEG-PLL) as a Non-Viral Vector to Enhance Gene Transfection. Int J Mol Sci 2011; 12:1371-88.
65. Park JS, Na K, Woo DG, et al. Non-viral gene delivery of DNA polyplexed with nanoparticles transfected into human mesenchymal stem cells. Biomaterials 2010; 31:124-32.
66. Warren D, Laxmikanthan G, Landy A. A chimeric Cre recombinase with regulated directionality. Proc Natl Acad Sci USA 2008; 105: 18278-83.
67. Muramatsu M, Hanazono Y, Ogasawara Y, et al. Reversible integration of the dominant negative retinoid receptor gene for ex vivo expansion of hematopoietic stem/progenitor cells. Biochem Biophys Res Commun 2001; 285: 891-6.
68. Lindenbaum M, Perkins E, Csonka E, et al. A mammalian artificial chromosome engineering system (ACE System) applicable to biopharmaceutical protein production, transgenesis and gene-based cell therapy. Nucleic Acids Res 2004;32:e172.
69. Chavez CL and Calos MP. Therapeutic Applications of the PhiC31 Integrase System. Curr Gene Ther 2011; 11:375-81.
70. Aronovich EL, McIvor RS, Hackett PB. The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet 2011; 20: R14-20.
71. Ivics Z, Katzer A, Stüwe EE, Fiedler D, Knespel S, Izsvák Z. Targeted Sleeping Beauty transposition in human cells. Mol Ther 2007; 15: 1137-44.
72. Hackett PB, Aronovich EL, Hunter D, et al. Efficacy and Safety of Sleeping Beauty Transposon-Mediated Gene Transfer in Preclinical Animal Studies. Curr Gene Ther 2011; 11:341-49.
73. Izsvak Z, Chuah MK, Vandendriessche T, Ivics Z. Efficient stable gene transfer into human cells by the Sleeping Beauty transposon vectors. Methods 2009; 49: 287-97.
74. Carroll D. Zinc-Finger Nucleases: A Panoramic View. Curr Gene Ther 2011; 11:2-10.
75. Silva G, Poirot L, Galetto R. Meganucleases and Other Tools for Targeted Genome Engineering: Perspectives and Challenges for Gene Therapy. Curr Gene Ther 2011; 11: 11-27.
76. Bogdanove AJ, Voytas DF. TAL effectors: customizable proteins for DNA targeting. Science 2011; 333: 1843-6.
77. Murthy RC, McFarland TJ, Yoken J, et al. Corneal transduction to inhibit angiogenesis and graft failure. Invest Ophth Vis Sci 2003; 44: 1837-42.
78. MacLaren RE, Pearson RA, MacNeil A, et al. Retinal repair by transplantation of photoreceptor precursors. Nature 2006; 444: 203-7.
79. Nakamura T, Kinoshita S. New hopes and strategies for the treatment of severe ocular surface disease. Curr Opin Ophthalmol 2011; 22: 274-8.
80. Stitt AW, O'Neill CL, O'Doherty MT, Archer DB, Gardiner TA, Medina RJ. Vascular stem cells and ischaemic retinopathies. Prog Retin Eye Res 2011; 30: 149-66.
81. Joe AW, Gregory-Evans K. Mesenchymal stem cells and potential applications in treating ocular disease. Curr Eye Res 2010; 35: 941-52.
82. Hu DN, Ritch R, McCormick SA, Pelton-Henrion K. Isolation and cultivation of human iris pigment epithelium. Invest Ophth Vis Sci 1992; 33: 2443-53.
83. Semkova I, Kreppel F, Welsandt G, et al. Autologous transplantation of genetically modified iris pigment epithelial cells: a promising concept for the treatment of age-related macular degeneration and other disorders of the eye. Proc Natl Acad Sci USA 2002; 99: 13090-5.
84. Abe T, Yoshida M, Yoshioka Y, et al. Iris pigment epithelial cell transplantation for degenerative retinal diseases. Prog Retin Eye Res 2007; 26: 302-21.
85. Gregory-Evans K, Po K, Chang F, Gregory-Evans CY. Pharmacological enhancement of ex vivo gene therapy neuroprotection in a rodent model of retinal degeneration. Ophthalmic Res 2011; 47: 32-8.
86. Brouard N, Chapel A, Thierry D, Charbord P, Peault B. Transplantation of gene modified human bone marrow stromal cells into mouse-human bone chimeras. J Hematother Stem Cell Res 2000; 9: 175-81.
87. Ding L, Lu S, Batchu R, Iii RS, Munshi N. Bone marrow stromal cells as a vehicle for gene transfer. Gene Ther 1999; 6: 1611-6.
88. Mosca JD, Hendricks JK, Buyaner D, et al. Mesenchymal stem cells as vehicles for gene delivery. Clin Orthop Relat Res 2000; 379 Suppl; S71-S90.
89. Meyerrose T, Olson S, Pontow S, et al. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev 2010; 62: 1167-74.
90. Eliopoulos N, Al-Khaldi A, Crosato M, Lachapelle K, Galipeau J. A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice, Gene Ther 2003; 10: 478-89.
91. Eliopoulos N, Gagnon RF, Francois M, Galipeau J. Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure, J. Am. Soc. Nephrol 2006; 17: 1576-84.
92. Kucic T, Copland IB, Cuerquis J, et al. Mesenchymal stromal cells genetically engineered to overexpress IGF-I enhance cell-based gene therapy of renal failureinduced anemia, Am. J. Physiol. Ren. Physiol 2008; 295: F488-F496.
93. Xu J, Qu J, Cao L, et al. Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice, J. Pathol 2008; 214: 472-81.
94. Meyerrose TE, Roberts M, Ohlemiller KK, et al. Lentiviraltransduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease, Stem Cells 2008; 26: 1713-22.
95. Sadan O, Shemesh N, Barzilay R, et al. Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging. Stem Cells 2008; 26: 2542-51.
96. Levy YS, Bahat-Stroomza M, Barzilay R, et al. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy 2008; 10: 340-52.
97. Sadan O, Bahat-Stromza M, Barhum Y, et al. Protective effects of neurotrophic factors secreting cells in a 6OHDA rat model of Parkinson disease. Stem Cells Dev 2009; 18: 1179-1190.
98. Levkovitch-Verbin H, Sadan O, Vander S, et al. Intravitreal injections of neurotrophic factors secreting mesenchymal stem cells are neuroprotective in rat eyes following optic nerve transection. Invest Ophthalmol Vis Sci 2010; 51: 6394-400.
99. Ellis J, Bhatia M. iPSC Technology: Platform for Drug Discovery. Clin Pharm Ther 2011; 89: 639-41.
100. Yamanaka S. A fresh look at iPS cells. Cell 2009; 137: 13-7.
101. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009; 4: 381-4.
102. Cho HJ, Lee CS, Kwon YW, et al. Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation. Blood 2010; 116: 386-95.
103. Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Gene Dev 2010; 24: 2239-63.
104. Desponts C, Ding S. Using small molecules to improve generation of induced pluripotent stem cells from somatic cells. Meth Mol Biol 2010; 636: 207-18.
105. Yu J, Vodyanik MA, Smuga-Otto K. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318: 1917-20.
106. Meyer JS, Shearer RL, Capowski EE et al. Modeling early retinal development with human embryonic and induced pluripotent stem cells. Proc Natl Acad Sci USA 2009; 106: 16698-703.
107. Gamm DM, Meyer JS. Directed differentiation of human induced pluripotent stem cells: a retina perspective. Regen Med 2010; 5: 315-317.
108. Hu BY, Weick JP, Yu J et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Natl Acad. Sci. USA 2010; 107: 4335-40.
109. Gögel S, Gubernator M, Minger SL. Progress and prospects: stem cells and neurological diseases. Gene Ther 2011;18:1-6.
110. Pearson RA, Barber AC, West EL et al. Targeted disruption of outer limiting membrane junctional proteins (Crb1 and ZO-1) increases integration of transplanted photoreceptor precursors into the adult wild-type and degenerating retina. Cell Transplant 2010; 19: 487-503.
111. Vinores SA, Derevjanik NL, Ozaki H, Okamoto N, Campochiaro PA. Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. Doc Ophthalmol 1999; 97: 217-28.
112. Gamm DM, Wang S, Lu B et al. Protection of visual functions by human neural progenitors in a rat model of retinal disease. PLoS One 2007; 2: e338.
113. Wang S, Lu B, Girman S et al. Non-invasive stem cell therapy in a rat model for retinal degeneration and vascular pathology. PLoS One 2010; 5: e9200.
114. Moloney TC, Rooney GE, Barry FP, Howard L, Dowd E. Potential of rat bone marrow-derived mesenchymal stem cells as vehicles for delivery of neurotrophins to the Parkinsonian rat brain. Brain Res 2010; 1359: 33-43.
115. Chang DY, Yoo SW, Hong Y et al. The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. Int J Cancer 2010; 127: 1975-83.
116. Yasuhara T, Borlongan CV, Date I. Ex vivo gene therapy: transplantation of neurotrophic factor-secreting cells for cerebral ischemia. Front Biosci 2006; 11: 760-75.
117. Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J 2010; 16: 336-341.
118. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nature Rev. Immunol 2009; 9: 704-716.
119. Chien KR, Domian IJ, Parker KK. Cardiogenesis and the complex biology of regenerative cardiovascular medicine. Science 2008; 322: 1494-1497.
120. Lindvall, O. & Kokaia, Z. Stem cells in human neurodegenerative disorders-time for clinical translation? J Clin Invest 2010; 120: 29-40.
121. Conti, L. & Cattaneo, E. Neural stem cell systems: physiological players or in vitro entities? Nature Rev. Neurosci 2010; 11: 176-187.
122. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ 2001; 79: 214-21.
123. Williams KA, Esterman J, Bartlett C, et al. How effective is corneal transplantation? Factors influencing long-term outcome in multivariate analysis. Transplantation 2006; 81: 896-901.
124. Williams KA, Jessup CF, Coster DJ. Gene therapy approaches to prolonging corneal allograft survival. Expert Opin Biol Ther 2004; 4: 1059-71.
125. Qian Y, Leong FL, Kazlauskas A, Reza Dana M. Ex vivo adenovirus-mediated gene transfer to corneal graft endothelial cells in mice. Invest Ophthalmol Vis Sci 2004; 45: 2187-93.
126. Parker DG, Brereton HM, Coster DJ, Williams KA. The potential of viral vector-mediated gene transfer to prolong corneal allograft survival. Curr Gene Ther 2009; 9: 33-44.
127. Williams KA, Brereton HM, Coster DJ. Prospects for genetic modulation of corneal graft survival. Eye 2009; 23: 1904-9.
128. Barcia RN, Dana MR, Kazlauskus A. Corneal graft rejection is accompanied by apoptosis of the endothelium and is prevented by gene therapy with Bcl-xL. Am J Transplant 2007; 7: 2082-9.
129. Fuchsluger TA, Jurkunas U, Kazlauskas A, Dana R. Anti-apoptotic gene therapy prolongs survival of corneal endothelial cells during storage. Gene Ther 2011; 18: 778-87.
130. Klebe S, Sykes PJ, Coster DJ, Krishnan R, Williams KA. Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation 2001; 71: 1214-20.
131. Parker DG, Coster D, Brereton HM, et al. Lentivirus-mediated gene transfer of interleukin 10 to the ovine and human cornea. Clin Experiment Ophthalmol 2010; 38: 405-13.
132. Sharma A, Tovey JC, Ghosh A, Mohan RR. AAV serotype influences gene transfer in corneal stroma in vivo. Exp Eye Res 2010; 91: 440-8.
133. Pleyer U, Groth D, Hinz B et al. Efficiency and toxicity of liposome-mediated gene transfer to corneal endothelial cells. Exp Eye Res 2001; 73: 1-7.
134. He Z, Pipparelli A, Manissolle C et al. Ex vivo gene electrotransfer to the endothelium of organ cultured human corneas. Ophthalmic Res 2010; 43: 43-55
135. Collins L, Fabre JW. A synthetic peptide vector system for optimal gene delivery to corneal endothelium. J Gene Med 2004; 6: 185-194.
136. Muller A, Zhang EP, Schroff M, Wittig B, Hoffmann F. Influence of ballistic gene transfer on antigen-presenting cells in murine corneas. Graefes Arch Clin Exp Ophthalmol 2002; 240: 851-9,
137. Zhang EP, Franke J, Schroff M, Junghans C, Wittig B, Hoffmann F. Ballistic CTLA4 and IL-4 gene transfer into the lower lid prolongs orthotopic corneal graft survival in mice. Graefes Arch Clin Exp Ophthalmol 2003; 241: 921-6.
138. Murthy RC, McFarland TJ, Yoken J, et al. Corneal transduction to inhibit angiogenesis and graft failure. Invest Opthalmol Vis Sci 2003; 44: 1837-42.
139. Yang K, Jiang Z, Wang D, Lian X, Yang T. Hair follicle stem cells to produce new corneas-upreg of Pax6 (using conditioned media) makes cornea-epithelial like cells. Corneal epithelial-like transdifferentiation of hair follicle stem cells is mediated by pax6 and betacatenin/ Lef-1. Cell Biol Int 2009; 33: 861-6.
140. Tian L, Yang P, Lei B, et al. AAV2-Mediated Subretinal Gene Transfer of hIFN-α Attenuates Experimental Autoimmune Uveoretinitis in Mice. PLoS One 2011; 6: e19542.
141. Broderick CA, Smith AJ, Balaggan KS, et al. Local administration of an adeno-associated viral vector expressing IL-10 reduces monocyte infiltration and subsequent photoreceptor damage during experimental autoimmune uveitis. Mol Ther 2005; 12: 369-73.
142. Tsai ML, Horng CT, Chen SL et al. Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist. Mol Vis 2009; 15: 1542-52.
143. Lyon F, Gale RP, Lightman S. Recent developments in the treatment of uveitis: an update. Expert Opin Investig Drugs 2009; 18: 609-16.
144. Tey S, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol. Blood Marrow Transplant 2007; 13: 913-24.
145. Ciceri F, Bonini C, Stanghellini MTL, et al. Infusion of suicidegene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489-500.
146. Fan BJ, Wiggs JL. Glaucoma: genes, phenotypes, and new directions for therapy. J Clin Invest 2010; 120: 3064-72.
147. Pease ME, McKinnon SJ, Quigley HA, et al. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci 2000; 41: 764-74.
148. Murphy JA, Clarke DB. Target-derived neurotrophins may influence the survival of adult retinal ganglion cells when local neurotrophic support is disrupted: implications for glaucoma. Med Hypotheses 2006; 67: 1208-12.
149. Harper MM, Grozdanic SD, Blits B, et al. Transplantation of BDNF-Secreting Mesenchymal Stem Cells Provides Neuroprotection in Chronically Hypertensive Rat Eyes. Invest Ophthalmol Vis Sci 2011; 52: 4506-15.
150. Fu QL, Li X, Yip HK, et al. Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma. Neuroscience 2009; 162: 375-82.
151. Parameswaran S, Balasubramanian S, Babai N, et al. Induced pluripotent stem cells generate both retinal ganglion cells and photoreceptors: therapeutic implications in degenerative changes in glaucoma and age-related macular degeneration. Stem Cells 2010; 28: 695-703.
152. Kelley MJ, Rose AY, Keller KE, Hessle H, Samples JR, Acott TS. Stem cells in the trabecular meshwork: present and future promises. Exp Eye Res 2009; 88: 747-51.
153. Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2009; 87: 450-4.
154. Barraza RA, McLaren JW, Poeschla EM. Prostaglandin pathway gene therapy for sustained reduction of intraocular pressure. Mol Ther 2010; 18: 491-501.
155. Spiga MG, Borras T. Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma. Invest Ophthalmol Vis Sci 2010; 51: 3029-41.
156. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008. Eye 2010; 24: 1692-9.
157. Tropepe V, Coles BLK, Chaisson BJ, et al. Retinal stem cells in the adult mouse eye. Science 2000; 287: 2032-6.
158. Cicero SA, Johnson D, Reyntjens S, et al. Cells previously identified as retinal stem cells are pigmented ciliary epithelial cells. Proc Natl Acad Sci USA 2009; 106: 6685-90.
159. Akagi T, Akita J, Haruta M, et al. Iris derived cells from adult rodents and primates adopt photoreceptor-specific phenotypes. Invest Ophthalmol Vis Sci 2005; 46: 3411-9.
160. Li X, Ma W, Zhuo Y, Yan RT, Wang SZ. Using neurogenin to reprogram chick RPE to produce photoreceptor-like neurons. Invest Ophthalmol Vis Sci 2010; 51: 516-25.
161. Mao W, Yan RT, Wang SZ. Reprogramming chick RPE progeny cells to differentiate towards retinal neurons by ash1. Mol Vis 2008; 14: 2309-20.
162. Wang SZ, Ma W, Yan RT, Mao W. Generating retinal neurons by reprogramming retinal pigment epithelialcells. Expert Opin Biol Ther 2010; 10: 1227-39.
163. Osakada F, Jin ZB, Hirami Y, Ikeda H, et al. In vitro differentiation of retinal cells from human pluripotent stem cells by smallmolecule induction. J Cell Sci 2009; 122: 3169-79.
164. Chen M, Chen Q, Sun X et al Generation of retinal ganglion-like cells from reprogrammed mouse fibroblasts. Invest Ophthalmol Vis Sci 2010; 51: 5970-8.
165. Liao JL, Yu J, Huang K, et al. Molecular signature of primary retinal pigment epithelium and stem-cell-derived RPE cells. Hum Mol Genet 2010; 19: 4229-38.
166. Semkova, I, Kreppel F, Welsandt G, et al. Autologous transplantation of genetically modified iris pigment epithelial cells: a promising concept for the treatment of age-related macular degeneration and other disorders of the eye. Proc Natl Acad Sci USA 2002; 99: 13090-5.
167. Abe T, Yoshida M, Yoshioka Y, et al. Iris pigment epithelial cell transplantation for degenerative retinal diseases. Prog Retin Eye Res. 2007; 26: 302-21.
168. Zhou XM, Yuan HP, Wu DL, et al. Study of brain derived neurotrophic factor gene transgenic neural stem cells in the rat retina. Chin Med J (Engl) 2009; 122: 1642-9.
169. Abe T, Wakusawa R, Seto H, Asai N, Saito T, Nishida K. Topical doxycycline can induce expression of BDNF in transduced retinal pigment epithelial cells transplanted into the subretinal space. Invest Ophthalmol Vis Sci 2008; 49: 3631-9.
170. Rubio F, Kokaia Z, Arco A, et al. BDNF gene transfer to the mammalian brain using CNS-derived neural precursors. Gene Ther 1999; 6: 1851-66.
171. Grill R, Murai K, Blesch A, Gage FH, Tuszynski MH. Cellular delivery of neurotrophin-3 promotes corticospinal axonal growth and partial functional recovery after spinal cord injury. J. Neurosci 1997; 17: 5560-72.
172. Pineda JR, Rubio N, Akerud P, et al. Neuroprotection by GDNFsecreting stem cells in a Huntington's disease model: optical neuroimage tracking of brain-grafted cells. Gene Ther 2007; 14: 118-28.
173. Kanter-Schlifke I, Fjord-Larsen L, Kusk P, Angehagen M, Wahlberg L, Kokaia M. GDNF released from encapsulated cells suppresses seizure activity in the epileptic hippocampus. Exp Neurol 2009; 216: 413-19.
174. Andsberg G, Kokaia Z, Bjorklund A, Lindvall O, Martinez-Serrano A. Amelioration of ischaemia-induced neuronal death in the rat striatum by NGF-secreting neural stem cells. Eur J Neurosci 1998; 10: 2026-36.
175. Lundberg C, Horellou P, Mallet J, Bjorklund A. Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model. Exp Neurol 1996; 139: 39-53.
176. Kim SU. Human neural stem cells genetically modified for brain repair in neurological disorders. Neuropathology 2004; 24: 159-71.
177. Behrstock SP, Anantharam V, Thompson KW, Schweitzer ES, Tobin AJ. Conditionally-immortalized astrocytic cell line expresses GAD and secretes GABA under tetracycline regulation. J Neurosci Res 2000; 60: 302-10.
178. Miki Y, Nonoguchi N, Ikeda N, Coffin RS, Kuroiwa T, Miyatake S. Vascular endothelial growth factor gene-transferred bone marrow stromal cells engineered with a herpes simplex virus type 1 vector can improve neurological deficits and reduce infarction volume in rat brain ischemia, Neurosurgery 2007; 61: 586-94.
179. Horita Y, Honmou O, Harada K, Houkin K, Hamada H, Kocsis JD, Intravenous administration of glial cell line-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in the adult rat. J Neurosci Res 2006; 84: 1495-504.
180. Onda T, Honmou O, Harada K, Houkin K, Hamada H, Kocsis JD. Therapeutic benefits by human mesenchymal stem cells (hMSCs) and Ang-1 gene-modified hMSCs after cerebral ischemia. J Cereb Blood Flow Metab 2008; 28: 329-40.
181. Zhao MZ, Nonoguchi N, Ikeda N, et al. Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector. J Cereb Blood Flow Metab 2006; 26: 1176-88.
182. Chong ZZ, Kang JQ, Maiese K. Erythropoietin: cytoprotection in vascular and neuronal cells. Curr Drug Targets Cardiovasc Haematol Disord 2003: 3; 141-154.
183. Sun Y, Calvert JW, Zhang JH. Neonatal hypoxia/ischemia is associated with decreased inflammatory mediators after erythropoietin administration. Stroke 2005; 36: 1672-1678.
184. Villa P, Bigini P, Mennini T, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198: 971-975.
185. Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment of acute ischaemic stroke. Stroke 2009; 40: e647-656.
186. Cho GW, Koh SH, Kim MH, et al. The neuroprotective effect of erythropoietin-transduced human mesenchymal stromal cells in an animal mode of ischemic stroke. Brain Res 2010; 1353: 1-13.
187. Thurman DJ, Alverson C, Dunn KA, Guerrero J, Sniezek JE. Traumatic brain injury in the United States: a public health perspective. J Head Trauma Rehab 1999; 14: 602-15.
188. Dougherty AL, MacGregor AJ, Han PP, Heltemes KJ, Galarneau MR. Visual dysfunction following blast-related traumatic brain injury from the battlefield. Brain Inj 2011; 25: 8-13.
189. Longhi L, Watson DJ, Saatman KE, et al. Ex vivo gene therapy using targeted engraftment of NGF-expressing human NT2N neurons attenuates cognitive deficits following traumatic brain injury in mice. J Neurotrauma 2004; 21: 1723-36.
190. Bakshi A, Shimizu S, Keck CA, et al. Neural progenitor cells engineered to secrete GDNF show enhanced survival, neuronal differentiation and improve cognitive function following traumatic brain injury. Eur J Neurosci 2006; 23: 2119-34.
191. Graves J, Balcer LJ. Eye disorders in patients with multiple sclerosis: natural history and management. Clin Ophthalmol 2010; 4: 1409-22.
192. Gold, R.; Linington, C.; Lassmann, H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129, 1953-1971.
193. Makar TK, Trisler D, Sura KT, Sultana S, Patel N, Bever CT. Brain derived neurotrophic factor treatment reduces inflammation and apoptosis in experimental allergic encephalomyelitis. J Neurol Sci 2008; 270: 70-76.
194. Makar TK, Bever CT, Singh IS, et al. Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J Neuroimmunol 2009; 210: 40-51.
195. Ko HJ, Chung JY, Nasa Z et al. Targeting MOG expression to dendritic cells delays onset of experimental autoimmune disease. Autoimmunity 2011; 44: 177-87.
196. Alderuccio F, Nasa Z, Chung J, Ko HJ, Chan J, Toh BH. Hematopoietic stem cell gene therapy as a treatment for autoimmune diseases. Mol Pharm 2011: 8: 1488-94.
197. Chan J, Ban EJ, Chun KH, et al. Transplantation of bone marrow transduced to express self-antigen establishes deletional tolerance and permanently remits autoimmune disease. J Immmunol 2008; 181: 7571-80.
198. Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009; 8: 244-53.
199. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000; 97: 12846-51.
200. Ehtesham M, Kabos P, Gutierrez MA et al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2002; 62: 7170-4.
201. Brown AB, Yang W, Schmidt NO et al. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum. Gene Ther 2003; 14: 1777-85.
202. Yuan X, Hu J, Belladonna ML, Black KL, Yu JS. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res 2006; 66: 2630-38.
203. Shimato S, Natsume A, Takeuchi H, et al. Human neural stem cells target and deliver therapeutic gene to experimental leptomeningeal medulloblastoma. Gene Ther 2007; 14: 1132-42.
204. Lorico A, Mercapide J, Solodushko V, Alexeyev M, Fodstad O, Rappa G. Primary neural stem/progenitor cells expressing endostatin or cytochrome P450 for gene therapy of glioblastoma. Cancer Gene Ther 2008; 15: 605-15.
205. Lee EX, Lam DH, Wu C, et al. Glioma gene therapy using induced pluripotent stem cell derived neural stem cells. Mol Pharm 2011; 8: 1515-24.